Estats Units - anglès - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - bimatoprost (unii: qxs94885mz) (bimatoprost - unii:qxs94885mz) - bimatoprost 0.3 mg in 1 ml - bimatoprost ophthalmic solution, 0.03% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. bimatoprost ophthalmic solution, 0.03% is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients [see adverse reactions (6.2)] . risk summary there are no adequate and well-controlled studies of bimatoprost ophthalmic solution, 0.03% administration in pregnant women. there is no increase in the risk of major birth defects or miscarriages based on bimatoprost postmarketing experience. in embryofetal developmental studies, administration of bimatoprost in pregnant mice and rats during organogensis, resulted in abortion and early delivery at oral doses at least 33 times (mice) or 94 times (rats) the human exposure at the recommended clinical dose (based on blood area under the curve [auc] levels). these adverse effects were not observed at 2.6 times (mice) and 47 times (rats) the human exposure at the recommended

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - bimatoprost 0,1 mg/ml - eye drops, solution - 0,1 mg/ml - bimatoprost 0.1 mg/ml - bimatoprost

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - bimatoprost 0,3 mg/ml - eye drops, solution - 0,3 mg/ml - bimatoprost 0.3 mg/ml - bimatoprost

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - bimatoprost 0,1 mg/ml - eye drops, solution - 0,1 mg/ml - bimatoprost 0.1 mg/ml - bimatoprost

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - bimatoprost 0,3 mg/ml - eye drops, solution in single-dose container - 0,3 mg/ml - bimatoprost 0.3 mg/ml - bimatoprost

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - bimatoprost, quantity: 300 microgram/ml - eye drops, solution - excipient ingredients: citric acid monohydrate; sodium chloride; dibasic sodium phosphate heptahydrate; hydrochloric acid; sodium hydroxide; purified water - lumigan pf is indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - bimatoprost 0.3 mg/ml;  ;   - eye drops, solution - 0.3 mg/ml - active: bimatoprost 0.3 mg/ml     excipient: benzalkonium chloride citric acid monohydrate dibasic sodium phosphate heptahydrate hydrochloric acid purified water sodium chloride sodium hydroxide - bimatoprost sandoz is indicated as monotherapy for the reduction of elevated intraocular pressure (iop) in patients with chronic glaucoma or ocular hypertension; or as adjunctive therapy in patients not adequately controlled on other agents.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - bimatoprost, quantity: 300 microgram/ml - eye drops - excipient ingredients: sodium hydroxide; hydrochloric acid; dibasic sodium phosphate; benzalkonium chloride; citric acid monohydrate; water for injections; sodium chloride - bimtop is indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta- blockers.

Israel - anglès - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - bimatoprost - ophthalmic solution - bimatoprost 0.3 mg / 1 ml - bimatoprost - reduction of elevated intraocular pressure in chronic open angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).

Israel - anglès - Ministry of Health

teva israel ltd - bimatoprost - ophthalmic solution - bimatoprost 0.3 mg / 1 ml - bimatoprost - reduction of elevated intraocular pressure in chronic open angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).